Language:

Adjuvant chemotherapy for gastric cancer: a randomised phase 3 trial of mitomycin-C plus either short-term doxifluridine or long-term doxifluridine plus cisplatin after curative D2 gastrectomy (AMC0201)

British journal of cancer, 2013-04, Vol.108 (6), p.1245-1251 [Peer Reviewed Journal]

2014 INIST-CNRS ;Copyright Nature Publishing Group Apr 2, 2013 ;Copyright © 2013 Cancer Research UK 2013 Cancer Research UK ;ISSN: 0007-0920 ;EISSN: 1532-1827 ;DOI: 10.1038/bjc.2013.86 ;PMID: 23449357 ;CODEN: BJCAAI

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Adjuvant chemotherapy for gastric cancer: a randomised phase 3 trial of mitomycin-C plus either short-term doxifluridine or long-term doxifluridine plus cisplatin after curative D2 gastrectomy (AMC0201)
Author: KANG, Y.-K ; CHANG, H.-M ; PARK, Y. S ; LEE, J.-L ; KIM, T. W ; OH, S. T ; PARK, B. K ; JUNG, H.-Y ; KIM, B. S ; YOOK, J. H ; RYU, M.-H ; PARK, I ; MIN, Y. J ; ZANG, D. Y ; KIM, G. Y ; YANG, D. H ; JANG, S. J
Subjects: Adolescent ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Cisplatin - administration & dosage ; Clinical Study ; Female ; Floxuridine - administration & dosage ; Follow-Up Studies ; Gastrectomy ; Gastroenterology. Liver. Pancreas. Abdomen ; Humans ; Lymphatic Metastasis ; Male ; Medical sciences ; Middle Aged ; Mitomycin - administration & dosage ; Neoplasm Recurrence, Local - drug therapy ; Neoplasm Recurrence, Local - mortality ; Neoplasm Recurrence, Local - surgery ; Neoplasm Staging ; Prognosis ; Prospective Studies ; Stomach Neoplasms - drug therapy ; Stomach Neoplasms - mortality ; Stomach Neoplasms - surgery ; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus ; Survival Rate ; Time Factors ; Tumors ; Young Adult
Is Part Of: British journal of cancer, 2013-04, Vol.108 (6), p.1245-1251
Description: This phase 3 study evaluated the efficacy of new adjuvant chemotherapy (MFP), which intensified the mitomycin-C (MMC) plus short-term doxifluridine (Mf) for gastric cancer. A total of 855 patients (424 in Mf, 431 in MFP) with pathological stage II-IV (M0) gastric cancer after D2 gastrectomy were randomly assigned to receive either Mf (MMC 20 mg m(-2), followed by oral doxifluridine 460-600 mg m(-2) per day for 3 months) or MFP (MMC 20 mg m(-2), followed by oral doxifluridine 460-600 mg m(-2) per day for 12 months with 6 monthly infusions of 60 mg m(-2) of cisplatin) chemotherapy. With a median follow-up of 6.6 years, there was no difference between the two groups in recurrence-free survival (RFS) (5-year RFS 61.1% in Mf and 57.9% in MFP; hazard ratio 1.10 (95% CI 0.89-1.35); P=0.39) and overall survival (OS) (5-year OS 66.5% in Mf and 65.0% in MFP; hazard ratio 1.11 (95% CI 0.89-1.39); P=0.33). Intensification of Mf adjuvant chemotherapy by prolonging the duration of oral fluoropyrimidine and adding cisplatin was safe but not effective to improve the survivals in curatively resected gastric cancer patients.
Publisher: Basingstoke: Nature Publishing Group
Language: English
Identifier: ISSN: 0007-0920
EISSN: 1532-1827
DOI: 10.1038/bjc.2013.86
PMID: 23449357
CODEN: BJCAAI
Source: Geneva Foundation Free Medical Journals
MEDLINE
PubMed Central
ProQuest Central

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Adjuvant chemotherapy for gastric cancer: a randomised phase 3 trial of mitomycin-C plus either short-term doxifluridine or long-term doxifluridine plus cisplatin after curative D2 gastrectomy (AMC0201)

2014 INIST-CNRS ;Copyright Nature Publishing Group Apr 2, 2013 ;Copyright © 2013 Cancer Research UK 2013 Cancer Research UK ;ISSN: 0007-0920 ;EISSN: 1532-1827 ;DOI: 10.1038/bjc.2013.86 ;PMID: 23449357 ;CODEN: BJCAAI

Searching Remote Databases, Please Wait